How to Reconstitute Epitalon: Syringe Selection and Needle Gauge Guide

What Is Epitalon and Why Does Reconstitution Technique Matter?

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) first isolated by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Preclinical research has examined its effects on telomerase activation, pineal gland function, and circadian melatonin regulation [1]. Because it is supplied as a lyophilized powder, every user must reconstitute it before injection. Poor technique at this stage can degrade the peptide, introduce contamination, or produce inaccurate doses.

Lyophilization removes water under vacuum to preserve peptide structure. Once you add diluent, the peptide re-enters aqueous solution and begins a slower degradation clock. USP General Chapter <1> defines a sterile preparation as one manufactured under conditions that prevent microbial contamination; bacteriostatic water achieves this through benzyl alcohol (0.9% w/v), which inhibits microbial growth without denaturing most small peptides [2].

Why Technique Errors Are Costly

A 10 mg Epitalon vial represents a significant financial and logistical investment. Reconstituting with tap water, saline without preservative, or sterile water (no bacteriostatic agent) shortens usable shelf life to 24 hours at most. Using the wrong syringe calibration produces dosing errors that can be 50 to 200% off the intended amount.

Regulatory Context for Compounded Peptides

Epitalon is not FDA-approved for human use. Compounded versions fall under Section 503A or 503B of the Drug Quality and Security Act, which means the compounder bears responsibility for sterility testing and beyond-use dating [3]. The FDA's guidance on compounded drug products specifies that beyond-use dates for non-sterile-to-sterile preparations must be assigned conservatively and that bacteriostatic agents extend stability only within defined temperature ranges [3].

Choosing the Right Diluent: Bacteriostatic Water vs. Alternatives

Bacteriostatic water for injection (BWFI) is the standard diluent for most research-grade peptides, including Epitalon. It contains 0.9% benzyl alcohol, which provides multi-dose antimicrobial protection across a typical 28-day use window.

Why Not Sterile Water for Injection?

Sterile water for injection (SWFI) contains no preservative. Once the septum is punctured, microbial contamination risk rises with each subsequent needle entry. SWFI is appropriate for single-use reconstitution only. For a peptide like Epitalon, where the full vial may be used across 5 to 10 injection events over several weeks, SWFI is a poor choice.

Why Not Normal Saline?

0.9% sodium chloride for injection (NS) is isotonic but also typically preservative-free in single-dose vials. Multi-dose NS vials containing benzyl alcohol exist but are labeled for intravenous admixture rather than subcutaneous injection diluent. NS may also interact with charged amino acid side chains in some peptides, though for short tetrapeptides like Epitalon this risk is low.

Benzyl Alcohol Safety Note

Benzyl alcohol at 0.9% is well-tolerated in adult subcutaneous preparations. The FDA does warn against its use in neonates (<28 days old), where it has been associated with "gasping syndrome" [4]. For adult use, the small per-injection exposure from BWFI is clinically negligible.

Diluent Volume Selection

The volume you add determines concentration, which drives the volume per dose you will draw. Two practical concentrations work for Epitalon:

| Diluent Added | Vial Size | Resulting Concentration | Volume for 5 mg Dose | Volume for 10 mg Dose | |---|---|---|---|---| | 1 mL BWFI | 10 mg | 10 mg/mL | 0.5 mL | 1.0 mL | | 2 mL BWFI | 10 mg | 5 mg/mL | 1.0 mL | 2.0 mL |

The 2 mL reconstitution (5 mg/mL) is generally preferable for users drawing 5 mg doses because it produces a 1.0 mL draw volume on a standard 1 mL syringe, which is easier to measure accurately than a 0.5 mL draw on the same syringe.

Syringe Selection: Insulin Syringes Explained

Insulin syringes are the standard tool for subcutaneous peptide injection. They are available in three barrel sizes: 0.3 mL (30 units), 0.5 mL (50 units), and 1.0 mL (100 units). The U-100 calibration means each unit marking equals 0.01 mL.

0.3 mL vs. 0.5 mL vs. 1.0 mL Barrels

0.3 mL (30-unit) syringe: Best for doses below 0.3 mL. Graduation marks are spaced further apart at this barrel size, making small volumes easier to read. If you reconstitute at 10 mg/mL and dose 2 mg, this syringe fits the 0.2 mL draw precisely.

0.5 mL (50-unit) syringe: The most commonly recommended barrel for Epitalon when reconstituted at 10 mg/mL (doses of 2.5 to 5 mg fall within 0.25 to 0.5 mL). Graduation in 1-unit (0.01 mL) increments allows for dose precision of ±0.05 mg per graduation error.

1.0 mL (100-unit) syringe: Necessary when reconstituted at 5 mg/mL and dosing 5 to 10 mg (draw volumes of 1.0 to 2.0 mL). For a 1 mL draw, this barrel is the only option. Note that 1.0 mL syringes have wider barrels, which can make sub-0.3 mL draws harder to read accurately.

Reading U-100 Markings Correctly

Each small graduation on a U-100 insulin syringe equals 1 unit, or 0.01 mL. To convert your desired mg dose to units:

1. Determine your concentration in mg/mL.
2. Divide dose (mg) by concentration (mg/mL) to get volume in mL.
3. Multiply mL by 100 to get units on the syringe.

Example: 5 mg dose, 5 mg/mL concentration. 5 ÷ 5 = 1.0 mL = 100 units. Draw to the 100-unit line on a 1 mL syringe.

Example: 5 mg dose, 10 mg/mL concentration. 5 ÷ 10 = 0.5 mL = 50 units. Draw to the 50-unit line on a 0.5 mL syringe.

Needle Gauge and Length: What the Evidence Supports

Needle gauge determines bore diameter. Higher gauge numbers mean thinner needles. For subcutaneous injections, the American Diabetes Association (ADA) Standards of Medical Care in Diabetes recommends 4 to 6 mm needle lengths and 28 to 32 gauge for insulin delivery [5]. Epitalon subcutaneous injections follow the same anatomical logic.

29 Gauge vs. 31 Gauge vs. 32 Gauge

29 gauge (0.33 mm outer diameter): Slightly wider bore than 31g or 32g. Flows easily, requires less plunger force, and is a reliable all-purpose choice. Most insulin syringes with attached needles are sold in 29g or 30g configurations.

31 gauge (0.25 mm OD): The most widely recommended gauge for subcutaneous peptide injections. Minimal discomfort, sufficient flow for aqueous peptide solutions, and widely available as fixed-needle insulin syringes. A randomized trial in insulin-using patients (N=130) found 31g needles produced significantly less pain than 27g equivalents, with no difference in insulin pharmacokinetics [6].

32 gauge (0.23 mm OD): Thinnest practical option. Very low pain, but plunger resistance is higher and flow is slower. Suitable for small volumes (under 0.3 mL). Less widely stocked.

Needle Length: 4 mm vs. 5/16 inch (8 mm) vs. 1/2 inch (12.7 mm)

For subcutaneous delivery at common injection sites (abdomen, thigh), a 4 to 8 mm needle length deposits the solution into subcutaneous fat rather than muscle, assuming a standard adult body composition. The ADA 2023 Standards of Care notes that "4-mm pen needles can be used regardless of BMI in adults" for insulin delivery and are preferred to longer needles to reduce inadvertent intramuscular injection [5].

For Epitalon:

• BMI <25: 4 to 5 mm (5/32 or 3/16 inch) needles are adequate.
• BMI 25 to 35: 5 to 8 mm (3/16 or 5/16 inch) needles.
• BMI >35: 8 mm (5/16 inch) may be needed at abdominal sites; a 4 mm needle with a 45-degree injection angle is an alternative.

Step-by-Step Reconstitution Protocol

Follow this sequence every time. Deviation at any step risks contamination or inaccurate dosing.

Materials Checklist

• Lyophilized Epitalon vial (10 mg)
• Bacteriostatic water for injection (BWFI), 10 mL multi-dose vial
• 18 to 21 gauge drawing needle (for pulling BWFI into the syringe)
• 29 to 31 gauge insulin syringe with fixed needle (for the subcutaneous injection itself)
• Alcohol swabs (70% isopropyl alcohol)
• Sharps container

Step 1: Workspace Preparation

Wipe down a flat, clean surface. Wash hands for 20 seconds with soap and water, then don clean nitrile gloves. Alcohol swab both the BWFI vial septum and the Epitalon vial septum. Allow each to air-dry for 15 to 30 seconds. Residual alcohol on the septum can introduce benzyl alcohol at higher-than-intended concentrations into the vial and may irritate subcutaneous tissue [2].

Step 2: Drawing the Diluent

Attach the 18 to 21 gauge drawing needle to a 3 mL or 5 mL syringe. Draw back the plunger to your target volume (1 mL or 2 mL) to create an air cushion. Insert the needle into the BWFI vial septum, inject the air, then invert the vial and withdraw the exact diluent volume needed.

Using a larger-bore drawing needle for this step protects the fine 29 to 31 gauge injection needle from septum-coring damage. The injection needle's tip is too delicate for septum puncture and should never contact a rubber stopper [2].

Step 3: Injecting Diluent Into the Peptide Vial

Point the Epitalon vial at a 45-degree angle. Insert the drawing needle through the septum and direct the stream of BWFI along the inner glass wall rather than directly onto the lyophilized cake. This prevents mechanical shearing of peptide structure. Do not shake the vial. Gently swirl for 30 to 60 seconds until the powder is fully dissolved. Epitalon typically dissolves quickly given its low molecular weight (390.4 Da).

Step 4: Inspecting the Reconstituted Solution

Hold the vial against a light source. The solution should be clear and colorless with no particulate matter. Any cloudiness, color change, or floating particles indicates possible contamination or degradation. Discard the vial if these signs appear. USP General Chapter <790> specifies visual inspection criteria for particulate matter in injections [7].

Step 5: Drawing the Injection Dose

Swap to your 29 to 31 gauge insulin syringe. Swab the reconstituted Epitalon vial septum again. Insert the needle, invert the vial, and withdraw the calculated volume. Remove any air bubbles by tapping the barrel and gently pressing the plunger until only solution remains.

Step 6: Injection Technique

Select the injection site (abdomen 2 inches from the navel, lateral thigh, or dorsal forearm). Swab the site and allow to dry. Pinch a fold of skin. Insert the needle at 45 to 90 degrees depending on needle length and body composition. Inject slowly over 3 to 5 seconds. Withdraw and apply gentle pressure without rubbing. Rotate sites with each injection to minimize lipohypertrophy [5].

Storage After Reconstitution

Reconstituted Epitalon should be stored upright in the original vial at 2 to 8°C (standard refrigerator temperature). Protect from light. Do not freeze the reconstituted solution.

Beyond-use dating for BWFI-reconstituted compounded peptides follows the principle that the benzyl alcohol preservative provides adequate antimicrobial protection for up to 28 days at refrigerated temperatures. USP General Chapter <797> (2023 revision) assigns beyond-use dates based on sterility category and storage conditions; Category 2 compounded sterile preparations stored at 2 to 8°C may have beyond-use dates up to 45 days, though most conservative compounding pharmacies assign 28 days for punctured multi-dose vials [8].

Lyophilized (unreconstituted) Epitalon vials should be stored at -20°C or below and protected from light and moisture. Once removed from the freezer, do not refreeze after reconstitution.

Epitalon Dosing Calculations: A Practical Calculator Framework

Common research-protocol dosing for Epitalon ranges from 5 mg to 10 mg per injection, administered once or twice daily, in cycles of 10 to 20 consecutive days. Some protocols describe a single annual cycle; others describe two cycles per year.

Quick-Reference Dosing Table

| Target Dose | Concentration (5 mg/mL, 2 mL recon) | Draw Volume | Syringe Units (U-100) | |---|---|---|---| | 2.5 mg | 5 mg/mL | 0.50 mL | 50 units | | 5 mg | 5 mg/mL | 1.00 mL | 100 units | | 10 mg | 5 mg/mL | 2.00 mL | Two separate 1 mL draws |

| Target Dose | Concentration (10 mg/mL, 1 mL recon) | Draw Volume | Syringe Units (U-100) | |---|---|---|---| | 2.5 mg | 10 mg/mL | 0.25 mL | 25 units | | 5 mg | 10 mg/mL | 0.50 mL | 50 units | | 10 mg | 10 mg/mL | 1.00 mL | 100 units |

For doses above 1 mL from a single syringe draw, the 1.0 mL insulin syringe is the only practical option. For 10 mg dosed at 5 mg/mL, the 2.0 mL volume exceeds any standard insulin syringe. In that scenario, either switch to a 10 mg/mL reconstitution (1 mL draw) or use two separate 0.5 mL injections at different sites.

Calculating Your Own Dose

The formula is:

Draw volume (mL) = Desired dose (mg) ÷ Reconstitution concentration (mg/mL)

Then multiply by 100 to convert mL to U-100 units.

If you reconstitute a 10 mg vial with 1.5 mL BWFI, concentration is 10 ÷ 1.5 = 6.67 mg/mL. A 5 mg dose requires 5 ÷ 6.67 = 0.75 mL = 75 units. Non-standard diluent volumes produce non-round concentrations that increase arithmetic error risk. Sticking to 1 mL or 2 mL diluent volumes minimizes this risk.

Epitalon's Research Background: What the Evidence Shows

Understanding why reconstitution precision matters requires knowing what Epitalon is proposed to do. Khavinson et al. Published a 2003 study showing that Epitalon increased telomerase activity in human fetal fibroblasts in vitro [1]. A subsequent cohort study following 266 elderly patients over 12 years found that those receiving peptide bioregulators (including epithalamin, the natural predecessor to synthetic Epitalon) had a 1.6-fold lower mortality rate compared to controls, though this study has significant methodological limitations including lack of blinding [9].

No large-scale randomized controlled trials of synthetic Epitalon in humans have been published as of 2025. The existing human data are predominantly from the Khavinson group and have not been independently replicated in blinded trials. The FDA has not reviewed or approved Epitalon for any indication.

As the Endocrine Society's 2019 position statement on anti-aging therapies notes: "No currently available intervention has been shown in human randomized trials to slow aging or extend maximum lifespan" [10]. Prescribers and patients should weigh this evidence gap against proposed benefits.

Safety Considerations and Contraindications

Injection Site Reactions

Subcutaneous peptide injections can produce transient erythema, pruritus, or minor induration at the injection site. These reactions are more common when technique is poor (angle too shallow, alcohol not fully dried, benzyl alcohol concentration elevated by error). Rotating sites reduces cumulative tissue irritation.

Benzyl Alcohol Sensitivity

A small minority of individuals have benzyl alcohol hypersensitivity. Symptoms range from localized urticaria to, rarely, anaphylaxis. Any systemic reaction after injection warrants immediate cessation and medical evaluation.

Contamination Risks

Every breach of aseptic technique raises infection risk. A 2021 CDC report on injection-related infections found that improper multi-dose vial handling was the most common source of healthcare-associated injection site infections [11]. The same principle applies to self-administered peptide injections.

No Pediatric, Pregnancy, or Breastfeeding Data

No safety data exist for Epitalon in pregnancy, lactation, or pediatric populations. Use in these groups cannot be supported by any available evidence.